Skip to main content

Table 1 Baseline characteristics of metachronous metastatic colorectal cancer patients by EGFR expression and KRAS mutation status

From: The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer

Characteristic EGFR positive (%) EGFR negative (%) Pvalue KRASWTa(%) KRASMutb(%) Pvalue
N = 67 (79.8%) N = 17 (20.2%) N = 54 (55.1%) N = 44 (44.9%)
Age (years, mean ± SD) 59.13 ± 10.49 64.41 ± 12.13 0.076 59.98 ± 10.21 59.18 ± 13.81 0.743
Gender    0.547    0.011
Male 37 (55.2) 8 (47.1)   36 (66.7) 18 (40.9)  
Female 30 (44.8) 9 (52.9)   18 (33.3) 26 (59.1)  
Tumor size    0.04    0.910
≥5 cm 18 (26.9) 9 (53.9)   19 (35.2) 15 (34.1)  
<5 cm 49 (73.1) 8 (47.1)   35 (64.8) 29 (65.9)  
Tumor location    0.518    0.130
Colon 45 (67.2) 10 (58.8)   30 (49.2) 31 (34.0)  
Rectum 22 (32.8) 7 (41.2)   24 (64.9) 13 (66.0)  
Histology    0.044    0.688
Well 1 (2.5) 1 (5.9)   1 (1.9) 1 (2.3)  
Moderately 62 (92.5) 12 (70.6)   45 (83.3) 39 (88.6)  
Poorly 4 (5.0) 4 (23.5)   8 (14.8) 4 (9.1)  
Histology    0.028    0.390
Well + Moderately 63 (94.0) 13 (76.5)   46 (85.2) 40 (90.9)  
Poorly 4 (6.0) 4 (23.5)   8 (14.8) 4 (9.1)  
AJCC stage (Initial diagnosis)    0.928    0.993
I 6 (9.0) 2 (11.8)   5 (9.3) 4 (9.1)  
II 19 (28.4) 5 (29.4)   14 (25.9) 11 (25.0)  
III 42 (62.6) 10 (58.8)   35 (64.8) 29 (65.9)  
Tumor depth    0.531    0.344
T1 0 (0) 0 (0)   1 (1.9) 0 (0.0)  
T2 8 (11.9) 2 (11.8)   4 (7.4) 6 (13.6)  
T3 48 (71.7) 14 (82.3)   39 (72.2) 34 (77.3)  
T4 11 (16.4) 1 (5.9)   10 (18.5) 4 (9.1)  
Lymph nodes metastases    0.755    0.401
N0 25 (37.3) 7 (41.2)   19 (35.2) 15 (34.1)  
N1 30 (44.8) 6 (35.3)   21 (38.9) 22 (50.0)  
N2 12 (17.9) 4 (23.5)   14 (25.9) 7 (15.9)  
Retrived LN c 14.50 ± 8.70 16.00 ± 7.18 0.594 14.98 ± 9.98 15.69 ± 9.26 0.742
Vascular invasion    0.701    0.053
Yes 23 (34.3) 5 (29.4)   25 (46.3) 12 (27.3)  
No 44 (65.75) 12 (70.6)   29 (53.7) 32 (72.7)  
Perineurial invasion    0.395    0.624
Yes 23 (34.3) 4 (23.5)   21 (38.9) 15 (34.1)  
No 44 (65.75) 13 (76.5)   33 (61.1) 29 (65.9)  
Pre-op serum CEA level    0.598    0.482
≥5 ng/ml 27 (40.3) 7 (41.2)   24 (44.4) 21 (47.7)  
<5 ng/ml 40 (59.7) 10 (58.8)   30 (55.6) 23 (52.3)  
Post-op serum CEA level    0.356    0.097
≥5 ng/ml 21 (31.3) 4 (23.5)   20 (37.0) 10 (22.7)  
<5 ng/ml 46 (68.7) 13 (76.5)   34 (63.0) 34 (77.3)  
Overall survival (months) 36.72 ± 18.68 62.51 ± 31.86 <0.001 42.54 ± 28.07 37.41 ± 17.23 0.293
Disease-free survival (months) 14.48 ± 9.91 34.27 ± 18.58 <0.001 18.38 ± 15.86 16.43 ± 10.58 0.487
  1. aWT: wild type; bMut: mutation; cLN: lymph node.